Patents Assigned to Prelude Corporation
  • Method of selection for treatment of subjects at risk of invasive breast cancer
    Patent number: 11821900
    Abstract: The present disclosure provides compositions and methods for the treatment of subjects having a risk of invasive breast cancer. In some embodiments, these aspects allow for the pairing of the proper treatment option for the particular subject. In some embodiments, this allows for identifying subjects who, while at risk for invasive breast cancer, will not normally respond to radiation therapy, and can instead receive an alternative therapy, such as a HER2 antibody.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: November 21, 2023
    Assignee: Prelude Corporation
    Inventor: Troy M. Bremer
  • DCIS recurrence and invasive breast cancer
    Patent number: 11543411
    Abstract: The present technology generally relates to methods and compositions relevant to the prediction that a subject with and/or after treatment for DCIS will experience a subsequent ipsilateral breast event that is a DCIS recurrence, an invasive breast cancer, both a DCIS recurrence and invasive cancer, or neither. The technology can assist one with how to treat such subjects.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 3, 2023
    Assignee: Prelude Corporation
    Inventors: Troy M. Bremer, Steven Paul Linke